Schizophrenia and type 2 diabetes are linked, but GLP-1s could help manage the risks
A study published in The Lancet Psychiatry suggests that GLP-1 receptor agonists, typically used for type 2 diabetes, are associated with lower risks of psychiatric hospitalizations in patients with schizophrenia. The findings indicate a potential dual benefit for patients managing both conditions.
Why it matters
This research could lead to improved treatment protocols for patients suffering from the co-occurrence of schizophrenia and metabolic disorders.
edited by Lisa Lock , reviewed by Alexander Pol
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Credit: David Trinks on Unsplash Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and psychiatric emergency department visits in people with both schizophrenia and type 2 diabetes (T2D), compared with no GLP-1 treatment or treatment with newer diabetes medications, according to new research published in The Lancet Psychiatry .
Schizophrenia is associated with an increased risk of T2D, and antipsychotic medications prescribed for schizophrenia also increase the risk of T2D. GLP-1s are an established class of diabetes medication used to treat people with T2D; however, whether GLP-1s affect the mental health of people with schizophrenia remains uncertain.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in